HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells

Nadire Duru, Ming Fan, Demet Candas, Cheikh Menaa, Hsin Chen Liu, Danupon Nantajit, Yunfei Wen, Kai Xiao, Angela Eldridge, Brett A. Chromy, Shiyong Li, Douglas R. Spitz, Kit Lam, Max S. Wicha, Jian-Jian Li

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Purpose: To understand the role of HER2-associated signaling network in breast cancer stem cells (BCSC) using radioresistant breast cancer cells and clinical recurrent breast cancers to evaluate HER2-targeted therapy as a tumor eliminating strategy for recurrent HER2-/low breast cancers. Experimental Design: HER2-expressing BCSCs (HER2+/CD44+/CD24-/low) were isolated from radiation-treated breast cancer MCF7 cells and in vivo irradiated MCF7 xenograft tumors. Tumor aggressiveness and radioresistance were analyzed by gap filling, Matrigel invasion, tumor-sphere formation, and clonogenic survival assays. The HER2/CD44 feature was analyzed in 40 primary and recurrent breast cancer specimens. Protein expression profiling in HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs was conducted with two-dimensional difference gel electrophoresis (2-D DIGE) and high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS) analysis and HER2-mediated signaling network was generated by MetaCore program. Results: Compared with HER2-negative BCSCs, HER2+/CD44+/CD24-/low cells showed elevated aldehyde dehydrogenase (ALDH) activity and aggressiveness tested by Matrigel invasion, tumor sphere formation, and in vivo tumorigenesis. The enhanced aggressive phenotype and radioresistance of the HER2+/CD44+/CD24-/low cells were markedly reduced by inhibition of HER2 via siRNA or Herceptin treatments. Clinical breast cancer specimens revealed that cells coexpressing HER2 and CD44 were more frequently detected in recurrent (84.6%) than primary tumors (57.1%). In addition, 2-D DIGE and HPLC/MS-MS of HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs reported a unique HER2- associated protein profile including effectors involved in tumor metastasis, apoptosis, mitochondrial function, and DNA repair. A specific feature of HER2-STAT3 network was identified. Conclusion: This study provides the evidence that HER2-mediated prosurvival signaling network is responsible for the aggressive phenotype of BCSCs that could be targeted to control the therapy-resistant HER2-/low breast cancer.

Original languageEnglish (US)
Pages (from-to)6634-6647
Number of pages14
JournalClinical Cancer Research
Volume18
Issue number24
DOIs
StatePublished - Dec 15 2012

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Neoplasms
High Pressure Liquid Chromatography
Two-Dimensional Difference Gel Electrophoresis
Phenotype
Aldehyde Dehydrogenase
MCF-7 Cells
Tandem Mass Spectrometry
Mitochondrial DNA
Heterografts
DNA Repair
Small Interfering RNA
Carcinogenesis
Proteins
Research Design
Radiation
Apoptosis
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. / Duru, Nadire; Fan, Ming; Candas, Demet; Menaa, Cheikh; Liu, Hsin Chen; Nantajit, Danupon; Wen, Yunfei; Xiao, Kai; Eldridge, Angela; Chromy, Brett A.; Li, Shiyong; Spitz, Douglas R.; Lam, Kit; Wicha, Max S.; Li, Jian-Jian.

In: Clinical Cancer Research, Vol. 18, No. 24, 15.12.2012, p. 6634-6647.

Research output: Contribution to journalArticle

Duru, N, Fan, M, Candas, D, Menaa, C, Liu, HC, Nantajit, D, Wen, Y, Xiao, K, Eldridge, A, Chromy, BA, Li, S, Spitz, DR, Lam, K, Wicha, MS & Li, J-J 2012, 'HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells', Clinical Cancer Research, vol. 18, no. 24, pp. 6634-6647. https://doi.org/10.1158/1078-0432.CCR-12-1436
Duru, Nadire ; Fan, Ming ; Candas, Demet ; Menaa, Cheikh ; Liu, Hsin Chen ; Nantajit, Danupon ; Wen, Yunfei ; Xiao, Kai ; Eldridge, Angela ; Chromy, Brett A. ; Li, Shiyong ; Spitz, Douglas R. ; Lam, Kit ; Wicha, Max S. ; Li, Jian-Jian. / HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 24. pp. 6634-6647.
@article{28292e6f3d1c40728b15e263e724a971,
title = "HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells",
abstract = "Purpose: To understand the role of HER2-associated signaling network in breast cancer stem cells (BCSC) using radioresistant breast cancer cells and clinical recurrent breast cancers to evaluate HER2-targeted therapy as a tumor eliminating strategy for recurrent HER2-/low breast cancers. Experimental Design: HER2-expressing BCSCs (HER2+/CD44+/CD24-/low) were isolated from radiation-treated breast cancer MCF7 cells and in vivo irradiated MCF7 xenograft tumors. Tumor aggressiveness and radioresistance were analyzed by gap filling, Matrigel invasion, tumor-sphere formation, and clonogenic survival assays. The HER2/CD44 feature was analyzed in 40 primary and recurrent breast cancer specimens. Protein expression profiling in HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs was conducted with two-dimensional difference gel electrophoresis (2-D DIGE) and high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS) analysis and HER2-mediated signaling network was generated by MetaCore program. Results: Compared with HER2-negative BCSCs, HER2+/CD44+/CD24-/low cells showed elevated aldehyde dehydrogenase (ALDH) activity and aggressiveness tested by Matrigel invasion, tumor sphere formation, and in vivo tumorigenesis. The enhanced aggressive phenotype and radioresistance of the HER2+/CD44+/CD24-/low cells were markedly reduced by inhibition of HER2 via siRNA or Herceptin treatments. Clinical breast cancer specimens revealed that cells coexpressing HER2 and CD44 were more frequently detected in recurrent (84.6{\%}) than primary tumors (57.1{\%}). In addition, 2-D DIGE and HPLC/MS-MS of HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs reported a unique HER2- associated protein profile including effectors involved in tumor metastasis, apoptosis, mitochondrial function, and DNA repair. A specific feature of HER2-STAT3 network was identified. Conclusion: This study provides the evidence that HER2-mediated prosurvival signaling network is responsible for the aggressive phenotype of BCSCs that could be targeted to control the therapy-resistant HER2-/low breast cancer.",
author = "Nadire Duru and Ming Fan and Demet Candas and Cheikh Menaa and Liu, {Hsin Chen} and Danupon Nantajit and Yunfei Wen and Kai Xiao and Angela Eldridge and Chromy, {Brett A.} and Shiyong Li and Spitz, {Douglas R.} and Kit Lam and Wicha, {Max S.} and Jian-Jian Li",
year = "2012",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-12-1436",
language = "English (US)",
volume = "18",
pages = "6634--6647",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells

AU - Duru, Nadire

AU - Fan, Ming

AU - Candas, Demet

AU - Menaa, Cheikh

AU - Liu, Hsin Chen

AU - Nantajit, Danupon

AU - Wen, Yunfei

AU - Xiao, Kai

AU - Eldridge, Angela

AU - Chromy, Brett A.

AU - Li, Shiyong

AU - Spitz, Douglas R.

AU - Lam, Kit

AU - Wicha, Max S.

AU - Li, Jian-Jian

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Purpose: To understand the role of HER2-associated signaling network in breast cancer stem cells (BCSC) using radioresistant breast cancer cells and clinical recurrent breast cancers to evaluate HER2-targeted therapy as a tumor eliminating strategy for recurrent HER2-/low breast cancers. Experimental Design: HER2-expressing BCSCs (HER2+/CD44+/CD24-/low) were isolated from radiation-treated breast cancer MCF7 cells and in vivo irradiated MCF7 xenograft tumors. Tumor aggressiveness and radioresistance were analyzed by gap filling, Matrigel invasion, tumor-sphere formation, and clonogenic survival assays. The HER2/CD44 feature was analyzed in 40 primary and recurrent breast cancer specimens. Protein expression profiling in HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs was conducted with two-dimensional difference gel electrophoresis (2-D DIGE) and high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS) analysis and HER2-mediated signaling network was generated by MetaCore program. Results: Compared with HER2-negative BCSCs, HER2+/CD44+/CD24-/low cells showed elevated aldehyde dehydrogenase (ALDH) activity and aggressiveness tested by Matrigel invasion, tumor sphere formation, and in vivo tumorigenesis. The enhanced aggressive phenotype and radioresistance of the HER2+/CD44+/CD24-/low cells were markedly reduced by inhibition of HER2 via siRNA or Herceptin treatments. Clinical breast cancer specimens revealed that cells coexpressing HER2 and CD44 were more frequently detected in recurrent (84.6%) than primary tumors (57.1%). In addition, 2-D DIGE and HPLC/MS-MS of HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs reported a unique HER2- associated protein profile including effectors involved in tumor metastasis, apoptosis, mitochondrial function, and DNA repair. A specific feature of HER2-STAT3 network was identified. Conclusion: This study provides the evidence that HER2-mediated prosurvival signaling network is responsible for the aggressive phenotype of BCSCs that could be targeted to control the therapy-resistant HER2-/low breast cancer.

AB - Purpose: To understand the role of HER2-associated signaling network in breast cancer stem cells (BCSC) using radioresistant breast cancer cells and clinical recurrent breast cancers to evaluate HER2-targeted therapy as a tumor eliminating strategy for recurrent HER2-/low breast cancers. Experimental Design: HER2-expressing BCSCs (HER2+/CD44+/CD24-/low) were isolated from radiation-treated breast cancer MCF7 cells and in vivo irradiated MCF7 xenograft tumors. Tumor aggressiveness and radioresistance were analyzed by gap filling, Matrigel invasion, tumor-sphere formation, and clonogenic survival assays. The HER2/CD44 feature was analyzed in 40 primary and recurrent breast cancer specimens. Protein expression profiling in HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs was conducted with two-dimensional difference gel electrophoresis (2-D DIGE) and high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS) analysis and HER2-mediated signaling network was generated by MetaCore program. Results: Compared with HER2-negative BCSCs, HER2+/CD44+/CD24-/low cells showed elevated aldehyde dehydrogenase (ALDH) activity and aggressiveness tested by Matrigel invasion, tumor sphere formation, and in vivo tumorigenesis. The enhanced aggressive phenotype and radioresistance of the HER2+/CD44+/CD24-/low cells were markedly reduced by inhibition of HER2 via siRNA or Herceptin treatments. Clinical breast cancer specimens revealed that cells coexpressing HER2 and CD44 were more frequently detected in recurrent (84.6%) than primary tumors (57.1%). In addition, 2-D DIGE and HPLC/MS-MS of HER2+/CD44+/CD24-/low versus HER2-/CD44+/CD24-/low BCSCs reported a unique HER2- associated protein profile including effectors involved in tumor metastasis, apoptosis, mitochondrial function, and DNA repair. A specific feature of HER2-STAT3 network was identified. Conclusion: This study provides the evidence that HER2-mediated prosurvival signaling network is responsible for the aggressive phenotype of BCSCs that could be targeted to control the therapy-resistant HER2-/low breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84871188682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871188682&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-1436

DO - 10.1158/1078-0432.CCR-12-1436

M3 - Article

C2 - 23091114

AN - SCOPUS:84871188682

VL - 18

SP - 6634

EP - 6647

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -